Intrust Bank NA Sells 991 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Intrust Bank NA trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 46.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,160 shares of the medical research company’s stock after selling 991 shares during the quarter. Intrust Bank NA’s holdings in Charles River Laboratories International were worth $214,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Fiduciary Financial Group LLC increased its stake in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after acquiring an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. M&T Bank Corp increased its position in Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after purchasing an additional 66 shares during the last quarter. Cornerstone Investment Partners LLC raised its stake in Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after purchasing an additional 69 shares in the last quarter. Finally, Metis Global Partners LLC raised its stake in Charles River Laboratories International by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 72 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 1.6 %

NYSE CRL opened at $155.60 on Monday. The stock has a market cap of $7.96 billion, a PE ratio of 1,037.35, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $273.32. The company’s 50-day moving average price is $164.69 and its 200-day moving average price is $182.60. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the firm earned $2.46 EPS. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on CRL. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Robert W. Baird decreased their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, UBS Group restated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $189.77.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).